Bangkok Lab and Cosmetic Public Company Limited, a manufacturer and distributor of modern medicines, herbal medicines, veterinary medicines, cosmetics, dietary supplements. under the company's trademark Ready to be traded on the Stock Exchange of Thailand on June 21, with a market capitalization at the IPO price of 6,300 million baht, using the trading symbol "BLC".
Mr. Manpong Senanarong, Deputy Manager, Head of Issuer Division The Stock Exchange of Thailand revealed that the Stock Exchange of Thailand welcomed Bangkok Lab and Cosmetic Public Company Limited to be listed and started trading on the stock market in the consumer products industry. Category of personal care and medical supplies By using the stock trading abbreviation "BLC" on June 21, 2023
BLC operates in the business of manufacturing and distributing pharmaceutical products. under all 485 trademarks, divided into types of modern drugs generic type It is a drug that has the same active ingredient as the original drug. or drugs that have expired patents under trademarks such as DiabeDerm, Glucosa, GASTRO BISMOL, medicinal herbal products such as Capsika, KACHANA, Plaivana, veterinary medicinal products, cosmetics, dietary supplements And other products by BLC, starting from the design and development of drug formulas according to pharmaceutical principles. And there is a BLC research center to apply modern technology and innovation. Including research and development to increase product value.
BLC has a paid-up capital after IPO of 300 million baht at a par value of 0.50 baht per share, initial public offering of 150 million ordinary shares, consisting of 120 million newly issued ordinary shares and existing ordinary shares of Viva Sonata Pte. , Ltd. in the amount of 30 million shares offered to individuals at the discretion of the underwriter. institutional investors Supporters, directors, executives and employees of the Company and its subsidiaries During June 14 - 16, 2023, at a price of 10.50 baht per share, representing a fundraising value of 1,260 million baht and having a securities value at the IPO price of 6,300 million baht, with KGI Securities (Thailand) Public Company Limited as an advisor. Finance and underwriters and underwriters of common stocks.
Prof. Suwit Ngampupan, Chief Executive Officer of Bangkok Lab and Cosmetic Public Company Limited, revealed that the company has a strategy for applying innovation and technology to develop new products. The company plans to use most of the funds raised for the construction of a new pharmaceutical factory. To increase production capacity by about 200% and invest in research and development of new generic drugs. The goal is to increase revenue to 2,000 million baht by 2026.
BLC's major shareholders after the IPO are founders Suwit Ngampuphan and his wife Ms. Sunisa Mongkol-Areepong, holding 37.2% of total shares, Mr. Somchai Pisphahutarn holding 15%, and Mr. Supachai Saibua holds 3.8% of shares. The company has a policy to pay dividends to shareholders at a rate of not less than 40% of net profit from the separate financial statements after deducting income tax.
Get a juristic person and legal reserve fund and the Company's Articles of Association, depending on the results of operations financial status business expansion plan and other suitability
Investors and interested people Please see details from the Company's prospectus at the SEC's website at www.sec.or.th. and general information of the company at www.blcplc.com and at www.set.or.th
Source: Thai News Agency